Low incidence of acute graft-versus-host disease, using unrelated HLA- A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T- cell antibodies

Transplantation

Volumn 66, Issue 5, 1998, Pages 620-625

  Ringden O ^a   Remberger, M ^a   Carlens, S ^a   Hagglund, H ^a   Mattsson, J ^a   Aschan, J ^a   Lonnqvist B ^a   Klaesson, S ^a   Winiarski, J ^a   Dalianis, T ^a   Olerup, O ^a   Sparrelid, E ^a   Elmhorn Rosenborg, A ^a   Svahn, B M ^a   Ljungman, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BACTEREMIA; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSION; INFANT; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 17344384211     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199809150-00013     Document Type: Article

References (40)

1. Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980; 303: 565.
2. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443.
3. Hows J, Bradley BA, Gore S, Downie T, Howard M, Gluckman E. The International Marrow Unrelated Search and Transplant (IMUST) Study: prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371.
4. Gale RP, Horowitz MM. Alternative donor transplants for leukemia. Bone Marrow Transplant 1993; 11(suppl 1): 66.
5. Ringdén O. Bone marrow transplantation using unrelated donors for haematological malignancies. Med Oncol 1997; 14: 11.
6. Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228.
7. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619.
8. Speiser DE, Tiercy JM, Rufer N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87: 4455.
9. Oakhill A, Pamphilon DH, Potter MN, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574.
10. Carlsson B, Wallin J, Böhme J, Möller E. HLA-DR-DQ haplo-types defined by restriction fragment analysis: correlation to serology. Hum Immunol 1987; 20: 95.
11. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225.
12. Ringdén O, Potter MN, Oakhill A, et al. Transplantation of peripheral blood progenitor cells from unrelated donors. Bone Marrow Transplant 1996; 17(suppl 2): 62.
13. Shaw PJ, Hugh-Jones K, Hobbs JR, et al. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1986; 1(2): 193.
14. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729.
15. Ringdén O, Bolme P, Lönnqvist B, et al. Bone marrow transplantation in children. Clin Transplant 1989; 3: 12.
16. Ringdén O, Pihlstedt P, Markling L, et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate: a randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221.
17. Aschan J. Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis. Bone Marrow Transplant 1994; 14: 601.
18. Schulman HM, Sullivan KM, Weiden P, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathological study of 20 Seattle patients. Am J Med 1980; 69: 204.
19. Ljungman P, Plotkin SA. Definitions, clinical severity scores, and new syndromes. Scand J Infect Dis 1995 (suppl) 99; 87.
20. Ljungman P, Lore K, Aschan J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583.
21. Remberger M, Ringdén O, Ljungman P, et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 22: 73.
22. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1990; 78: 2120.
23. Ringdén O, Klaesson S, Sundberg B, et al. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin as compared to monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992; 9: 19.
24. Ringdén O, Mattsson J, Aschan J, et al. Experience with HLA-A, -B and -DR identical unrelated stem cell transplantations using immunosuppression with ATG, cyclosporin and methotrexate. Royal College of Physicians of Edinburgh, Consensus Conference of Unrelated Donor Bone Marrow Transplantation, 1996; 25.
25. Hägglund H, Boström L, Remberger M, et al. Risk factors for acute graft-versus-host-disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747.
26. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching and marrow cell dose. Blood 1997; 89: 4226.
27. Ringdén O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose and splenectomy. Transplantation 1985; 40: 39.
28. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397.
29. Nash RA, Sullivan Pepe M, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838.
30. Boström L, Ringdén O, Gratama JW, et al. Leukaemia Working Party of the European Group for Bone Marrow Transplantation: a role of herpes virus serology for the development of acute graft-versus-host disease. Bone Marrow Transplant 1990; 5: 321.
31. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720.
32. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634.
33. Holler E, Kolb HJ, Mittermuller J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK) (195F). Blood 1995; 86: 890.
34. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223.
35. Weiden PL, Flournoy N, Thomas ED, et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979; 300: 1068.
36. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1989; 75: 555.
37. Ringdén O, Labopin M, Gluckman E, et al. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation: graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921.
38. Andstrom EE, Ringden O, Remberger M, Svahn BM, Tollemar J. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant. Mycoses 1996; 39: 185.
39. Ringdén O, Hägglund H, Runde V, et al. Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. Bone Marrow Transplant (in press).
40. + cell dose predicts survival, posttransplant morbidity and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223.